secwatch.observer — SEC 8-K summary
======================================

Issuer:     ENvue Medical, Inc. (FEED)
CIK:        0001326706
Form:       8-K
Filed at:   2023-11-14T23:59:59+00:00
Accession:  0001493152-23-040784
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NanoVibronix posts $458K Q3 revenue; CMS reimbursement request not approved
---------------------------------------------------------------------------

- Q3 2023 revenue of $458,000; operating loss of $670,000; year-to-date revenue up 22%, operating loss reduced ~20%.
- Raised $4.2M net from securities sales; cash & receivables $3.8M, inventory >$3.1M.
- UK NHS supply contract and Drug Tariff reimbursement effective Nov 1; UK distributor Peak Medical pursuing opportunities.
- Added Mio-Guard as exclusive distributor for Sports segment; VA and Workers Comp channels progressing.
- CMS denied full reimbursement again after August 2023 notification; company awaiting response after meeting with CMS leadership.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1326706/000149315223040784/0001493152-23-040784-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1326706/000149315223040784/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-040784

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer